Clinical Trial Update: Subcutaneous Immunotherapy Treatment for Patients With Hypersensitivity to Parietaria Judaica [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating subcutaneous immunotherapy for Parietaria judaica-induced allergic rhinoconjunctivitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Rhinoconjunctivitis

Drugs mentioned

• Parietaria judaica allergen subcutaneous immunotherapy

Snippet

Sponsor: Laboratorios Leti, S.L. | Conditions: Allergic Rhinoconjunctivitis | Phase 3 | Status: COMPLETED